The clinical performance is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of cardiac prognosis of AL requires individualized management, usually including drug therapy, rehabilitation, regular follow-up, and other multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of cardiac pulmonary embolism AL. The platform serves the China International Medical Service System, a team of domestically authorized experts in the field of infectious respiratory digestive endocrine disorders, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.